MENVEO ইস্রায়েল - ইংরেজি - Ministry of Health

menveo

glaxo smith kline (israel) ltd - meningococcal vaccines group a; meningococcal vaccines group c; meningococcal vaccines group w; meningococcal vaccines group y - powder and solution for solution for injection - meningococcal vaccines group y 5 mcg / 0.5 ml; meningococcal vaccines group w 5 mcg / 0.5 ml; meningococcal vaccines group c 5 mcg / 0.5 ml; meningococcal vaccines group a 10 mcg / 0.5 ml - other meningococcal monovalent purified polysaccharides antigen - other meningococcal monovalent purified polysaccharides antigen - menveo is indicated for active immunization of children (2 years of age and above), adolescents and adults up to the age of 55 years, at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations.

THROMBIN HUMAN powder, for solution মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

thrombin human powder, for solution

ethicon, inc - human thrombin (unii: 6k15abl77g) (human thrombin - unii:6k15abl77g) - human thrombin 2000 [iu] in 2 ml - evithrom® thrombin, topical (human), is indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. evithrom® thrombin, topical (human), may be used in conjunction with an absorbable gelatin sponge, usp. - do not use in individuals known to have an anaphylactic or severe systemic reaction to evithrom® or to human blood products. - do not use for the treatment of severe or brisk arterial bleeding. risk summary there are no data with evithrom® use in pregnant women to inform a drug-associated risk. animal reproduction studies have not been conducted with evithrom® . it is not known whether evithrom® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. evithrom® should be given to a pregnant woman only if clearly needed. in the u.s. general population, the estimated background

CERVARIX human papillomavirus vaccine types 16 and 18 [recombinant, AS04 adjuvanted] suspension for injection vial অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

cervarix human papillomavirus vaccine types 16 and 18 [recombinant, as04 adjuvanted] suspension for injection vial

glaxosmithkline australia pty ltd - hpv type 18 l1 protein, quantity: 20 microgram; hpv type 16 l1 protein, quantity: 20 microgram - injection, suspension - excipient ingredients: water for injections; sodium chloride; 3-o-desacyl-4'-monophosphoryl lipid a; monobasic sodium phosphate; aluminium hydroxide hydrate - cervarix is indicated in females from 10 to 45 years of age for the prevention of persistent infection, premalignant cervical lesions and cervical cancer caused by human papillomavirus types 16 and 18. immunogenicity studies have been conducted in females aged 10 to 14 years and 26 to 45 years to link efficacy in females aged 15 to 25 years to other populations. (see precautions and clinical trials). cervarix is indicated in females from 10 to 45 years for the prevention of cervical cancer by protecting against incident and persistent infections, cytological abnormalities including atypical squamous cells of undetermined significance (asc-us) and cervical intraepithelial neoplasia (cin), cin 1 and pre-cancerous lesions (cin 2 and cin 3) caused by human papillomavirus types 16 and 18. immunogenicity studies have been conducted in females aged 10 to 14 years and 26 to 45 years to link efficacy in females aged 15 to 25 years to other populations.

HUMAN PARVOVIRUS HOMOCHORD- parvovirus nosode liquid মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

human parvovirus homochord- parvovirus nosode liquid

deseret biologicals, inc. - human parvovirus b19 (unii: 94n635564t) (human parvovirus b19 - unii:94n635564t) - human parvovirus b19 15 in 1 ml - for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

HUMAN PARVOVIRUS REMEDY- parvovirus nosode (b19) liquid মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

human parvovirus remedy- parvovirus nosode (b19) liquid

deseret biologicals, inc - human parvovirus b19 (unii: 94n635564t) (human parvovirus b19 - unii:94n635564t) - human parvovirus b19 15 [hp_x] in 1 ml - for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration. for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration.

HUMAN PARVOVIRUS REMEDY- parvovirus liquid মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

human parvovirus remedy- parvovirus liquid

apotheca company - human parvovirus b19 (unii: 94n635564t) (human parvovirus b19 - unii:94n635564t) - human parvovirus b19 15 [hp_x] in 1 ml -     indications:  for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever. indications:   for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.